Inhaler manufacturers who have been purchasing acrylonitrile butadiene styrene (ABS) for inhaler housings from either BASF or Ineos will now have a new supplier: Styrolution. Ineos’s Lustran, Novodur, and Absolac brands and BASF’s Terluran brand will be sold by the new company, a 50/50 joint venture of BASF and Ineos, which is headquartered in Frankfurt/Main, Germany, with sites in Germany, Belgium, France, Sweden, Korea, India, Thailand, the USA, Canada and Mexico.
Jim Ratcliffe, Chairman of INEOS Capital, commented, “Styrolution has the people, the products and scale to compete effectively in world markets. Bringing together plant, products and entrepreneurial employees from BASF and INEOS into a new joint venture company with a clear strategy, provides a firm foundation for long-term success and growth.”
Martin Brudermüller, Vice Chairman of the Board of Executive Directors of BASF SE, added, “From day one Styrolution will be a global leader in its industry with an excellent competitive position. We are convinced that the decision to combine our styrenics activities in a joint venture is the right one.”
Read the BASF/Ineos press release.
